Market reaction and deal basics
Shares of Boundless Bio Inc (NASDAQ: BOLD) rose sharply in premarket trading, gaining 76.5% following the release of a definitive merger agreement with privately held Serapha Bio Inc. The companies said the transaction will be executed as an all-stock exchange, with the post-closing company operating under the Serapha Bio name and expected to list on the Nasdaq under the ticker symbol "AATD."
Pre-closing cash distribution
Prior to the closing of the merger, Boundless Bio plans to declare a cash dividend to its pre-merger stockholders estimated to be in the range of $44 million to $48 million.
Financing commitments and structure
Serapha reported commitments for roughly $230 million in private investments. The financing round is being co-led by RA Capital Management and RTW Investments, with additional participation from Janus Henderson Investors, Decheng Capital, Vivo Capital, Casdin Capital, and other investors. Of the committed total, $138 million has already been funded through a Series A financing. The remaining $92 million is expected to close substantially concurrently with the merger.
Clinical focus and data
Following the combination, the unified company will concentrate on advancing SERP-01, an investigational in vivo base editing therapy intended to treat Alpha-1 Antitrypsin Deficiency (AATD). The therapy is directed at the SERPINA1 E342K mutation. The companies state that proof-of-concept data demonstrated restoration of serum AAT to normal levels.
Ownership and capital runway
Under the transaction terms, pre-merger Boundless Bio stockholders are expected to hold approximately 3.7% of the combined company, while pre-merger Serapha stockholders - including investors participating in the pre-closing financings - are expected to own about 96.3%.
The companies said that the combined entity's cash and cash equivalents at closing, including proceeds from the private placement, are expected to fund operations into the second half of 2029. Management indicated this liquidity is intended to provide runway through completion of Phase 2 and initiation of Phase 3 for SERP-01.
Approvals and expected timetable
Both companies' boards have given unanimous approval to the transaction. The deal is anticipated to close in the fourth quarter of 2026, subject to stockholder approval, Nasdaq listing approval, and other customary closing conditions.
Note on article scope
This report focuses on the terms disclosed by the companies and the immediate market reaction. It reflects only the information released in the transaction announcement and does not add or infer details beyond what the companies provided.